Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 15/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.47 |
| ▸ | PTPRC | P08575 | 2/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165042 | 0.89 | PTPN1 (0.59) | PGK1PGK2PTPN1HDAC3HDAC1 | |
| SCHEMBL5166585 | 0.84 | PTPN1 (0.55) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5163005 | 0.82 | PTPN5 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5892025 | 0.82 | PGK1 (0.56) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL4316972 | 0.80 | PTPN1 (0.74) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5892082 | 0.77 | PTPN1 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL7660739 | 0.76 | PGK1 (0.59) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL5163594 | 0.76 | PGK1 (0.59) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL7188019 | 0.75 | PGK1 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 | |
| SCHEMBL7591720 | 0.75 | PGK1 (0.57) | PGK1PGK2PTPN1PTPN2PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | PGK1 1125/4885PGK2 958/4885PTPN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.